Abstract
Over the years much has been attempted to generate engineered cardiac tissue. One approach is culturing cells within engineered biodegradable scaffolds to provide temporary elastic support and to replace the necrotic cardiomyocytes. In particular, these engineered tissue construct have been of great interest as an implantable patch over a region of the myocardial infarct to stimulate the formation of micro-vessel growth and thus increase blood flow through the myocardium. For the successful revascularization after myocardial infarction, vascularization within three-dimensional engineered cardiac tissue construct has become important for stimulating the formation of a mature microvascular network. In this review, various approaches and recent advances in vascularization of engineered cardiac patch are highlighted and discussed.
Similar content being viewed by others
References
Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Prob Cardiology. 2010; 35:72–115.
Jaffe AS, Apple FS. The third universal definition of myocardial infarction—moving forward. Clin Chem. 2012; 58:1727–1728.
Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol. 2006; 48:907–913.
Stroncek JD, Reichert WM. Overview of wound healing in different tissue types. In: Reichert WM, editor. Indwelling neural implants: strategies for contending with the in vivo environment. Boca Raton (FL)2008.
Rane AA, Christman KL. Biomaterials for the treatment of myocardial infarction: a 5-year update. J Am Coll Cardiol. 2011; 58:2615–2629.
Del Re DP, Sadoshima J. Optimizing cell-based therapy for cardiac regeneration. Circulation. 2009; 120:831–834.
Hou D, Youssef EA, Brinton TJ, Zhang P, Rogers P, Price ET, Yeung AC, Johnstone BH, Yock PG, March KL. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation. 2005; 112:I150–I156.
Wang T, Jiang XJ, Tang QZ, Li XY, Lin T, Wu DQ, Zhang XZ, Okello E. Bone marrow stem cells implantation with alpha-cyclodextrin/MPEG-PCL-MPEG hydrogel improves cardiac function after myocardial infarction. Acta Biomater. 2009; 5:2939–2944.
Lesman A, Habib M, Caspi O, Gepstein A, Arbel G, Levenberg S, Gepstein L. Transplantation of a tissue-engineered human vascularized cardiac muscle. Tissue Eng Part A. 2010; 16:115–125.
Blanche C, Kamlot A, Blanche DA, Kearney B, Magliato KE, Czer LS, Trento A. Heart transplantation with donors fifty years of age and older. J Thorac Cardiovasc Surg. 2002; 123:810–815.
Troy BL, Pombo J, Rackley CE. Measurement of left ventricular wall thickness and mass by echocardiography. Circulation. 1972; 45:602–611.
Vunjak-Novakovic G, Tandon N, Godier A, Maidhof R, Marsano A, Martens TP, Radisic M. Challenges in cardiac tissue engineering. Tissue Eng Part B Rev. 2010; 16:169–187.
Finosh GT, Jayabalan M. Regenerative therapy and tissue engineering for the treatment of end-stage cardiac failure: new developments and challenges. Biomatter. 2012; 2:1–14.
Venugopal JR, Prabhakaran MP, Mukherjee S, Ravichandran R, Dan K, Ramakrishna S. Biomaterial strategies for alleviation of myocardial infarction. J R Soc Interface. 2012; 9:1–19.
Shannon AW, Harrigan RA. General pharmacologic treatment of acute myocardial infarction. Emerg Med Clin North Am. 2001; 19:417–431.
Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1607–1621.
Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Necciari J, Defreyn G, Maffrand JP. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 1993; 11:180–198.
Gregorini L, Marco J. Ticlopidine and aspirin interactions. Heart. 1997; 77:11–12.
Weaver WD. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials. Eur Heart J. 1996; 17Suppl F:9–15.
Ghali WA, Donaldson CR, Knudtson ML, Lewis SJ, Maxwell CJ, Tu JV. Rising to the challenge: transforming the treatment of ST-segment elevation myocardial infarction. CMAJ. 2003; 169:35–37.
Oxenham H, Sharpe N. Angiotensin-converting enzyme inhibitor treatment after myocardial infarction. A selective approach for maximum benefit. J Am Coll Cardiol. 2000; 36:2054–2055.
Aros F, Loma-Osorio A, Vila J, Lopez-Bescos L, Cunat J, Rodriguez E, San Jose JM, Heras M, Marrugat J. Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry. Rev Esp Cardiol. 2006; 59:313–320.
Blankenhorn DH, Hodis HN. Atherosclerosis—reversal with therapy. Western J Med. 1993; 159:172–179.
Zijlstra F. Angioplasty vs thrombolysis for acute myocardial infarction: a quantitative overview of the effects of interhospital transportation. Eur Heart J. 2003; 24:21–23.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115:2344–2351.
Betriu A, Masotti M, Serra A, Alonso J, Fernández-Avilés F, Gimeno F, Colman T, Zueco J, Delcan JL, Garcia E, Calabuig J. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START)A four-year follow-up. J Am Coll Cardiol. 1999; 34:1498–1506.
Eagle KA, Guyton RA, Davidoff R, Ewy GA, Fonger J, Gardner TJ, Gott JP, Herrmann HC, Marlow RA, Nugent W, O’Connor GT, Orszulak TA, Rieselbach RE, Winters WL, Yusuf S, Gibbons RJ, Alpert JS, Eagle KA, Gardner TJ, Garson A, Gregoratos G, Russell RO, Ryan TJ, Smith SC. ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). Circulation. 1999; 100:1464–1480.
Kellar RS, Shepherd BR, Larson DF, Naughton GK, Williams SK. Cardiac patch constructed from human fibroblasts attenuates reduction in cardiac function after acute infarct. Tissue Eng. 2005; 11:1678–1687.
Callegari A, Bollini S, Iop L, Chiavegato A, Torregrossa G, Pozzobon M, Gerosa G, De Coppi P, Elvassore N, Sartore S. Neovascularization induced by porous collagen scaffold implanted on intact and cryoinjured rat hearts. Biomaterials. 2007; 28:5449–5461.
Pozzobon M, Bollini S, Iop L, De Gaspari P, Chiavegato A, Rossi CA, Giuliani S, Fascetti Leon F, Elvassore N, Sartore S, De Coppi P. Human bone marrow-derived CD133(+) cells delivered to a collagen patch on cryoinjured rat heart promote angiogenesis and arteriogenesis. Cell Transplant. 2010; 19:1247–1260.
Naito H, Melnychenko I, Didié M, Schneiderbanger K, Schubert P, Rosenkranz S, Eschenhangen T, Zimmermann WH. Optimizing engineered heart tissue for therapeutic applications as surrogate heart muscle. Circulation. 2006; 114:I72–I78.
Dvir T, Kedem A, Ruvinov E, Levy O, Freeman I, Landa N, Holbova R, Feinberg MS, Dror S, Etzion Y, Leor J, Cohen S. Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Natl Acad Sci USA. 2009; 106:14990–14995.
Hanjaya-Putra D, Gerecht S. Preview. Mending the failing heart with a vascularized cardiac patch. Cell Stem Cell. 2009; 5:575–576.
Suzuki R, Hattori F, Itabashi Y, Yoshioka M, Yuasa S, Manabe-Kawaguchi H, Murata M, Makino S, Kokaji K, Yozu R, Fukuda K. Omentopexy enhances graft function in myocardial cell sheet transplantation. Biochem Biophys Res Commun. 2009; 387: 353–359.
Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282:1145–1147.
Watt FM, Hogan BL. Out of Eden: stem cells and their niches. Science. 2000; 287:1427–1430.
Mummery C, Ward-van Oostwaard D, Doevendans P, Spijker R, van den Brink S, Hassink R, van der Heyden M, Opthof T, Pera M, de la Riviere AB, Passier R, Tertoolen L. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation. 2003; 107:2733–2740.
Kehat I, Gepstein A, Spira A, Itskovitz-Eldor J, Gepstein L. High-resolution electrophysiological assessment of human embryonic stem cell-derived cardiomyocytes: a novel in vitro model for the study of conduction. Circ Res. 2002; 91:659–661.
Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, Livne E, Binah O, Itskovitz-Eldor J, Gepstein L. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest. 2001; 108:407–414.
Levenberg S, Golub JS, Amit M, Itskovitz-Eldor J, Langer R. Endothelial cells derived from human embryonic stem cells. Natl Acad Sci USA. 2002; 99:4391–4396.
Kim JH, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay R. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease. Nature. 2002; 418:50–56.
Bjorklund LM, Sánchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS, Brownell AL, Jenkins BG, Wahlestedt C, Kim KS, Isacson O. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Natl Acad Sci USA. 2002; 99:2344–2349.
Zhang SC, Wernig M, Duncan ID, Brüstle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol. 2001; 19:1129–1133.
Schuldiner M, Eiges R, Eden A, Yanuka O, Itskovitz-Eldor J, Goldstein RS, Benvenisty N. Induced neuronal differentiation of human embryonic stem cells. Brain Res. 2001; 913:201–205.
Reubinoff BE, Itsykson P, Turetsky T, Pera MF, Reinhartz E, Itzik A, Ben-Hur T. Neural progenitors from human embryonic stem cells. Nat Biotechnol. 2001; 19:1134–1140.
Graf T, Enver T. Forcing cells to change lineages. Nature. 2009; 462:587–594.
Cha C, Shin SR, Annabi N, Dokmeci MR, Khademhosseini A. Carbon-based nanomaterials: multifunctional materials for biomedical engineering. ACS Nano. 2013; 7:2891–2897.
Shin SR, Bae H, Cha JM, Mun JY, Chen YC, Tekin H, Shin H, Farshchi S, Dokmeci MR, Tang S, Khademhosseini A. Carbon nanotube reinforced hybrid microgels as scaffold materials for cell encapsulation. ACS Nano. 2012; 6:362–372.
Shin SR, Jung SM, Zalabany M, Kim K, Zorlutuna P, Kim SB, Nikkhah M, Khabiry M, Azize M, Kong J, Wan KT, Palacios T, Dokmeci MR, Bae H, Tang XS, Khademhosseini A. Carbonnanotube-embedded hydrogel sheets for engineering cardiac constructs and bioactuators. ACS Nano. 2013; 7:2369–2380.
Dvir T, Timko BP, Brigham MD, Naik SR, Karajanagi SS, Levy O, Jin H, Parker KK, Langer R, Kohane DS. Nanowired threedimensional cardiac patches. Nat Nanotechnol. 2011; 6:720–725.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, H., Bae, H. Forming vascular networks within functional cardiac tissue constructs. Biomed. Eng. Lett. 3, 138–143 (2013). https://doi.org/10.1007/s13534-013-0106-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13534-013-0106-y